Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ARAY
Previous Symbol
CUSIP00439710
Phone408-716-4600
Debt
Debt-to-Equity Ratio2.74
Current Ratio1.69
Quick Ratio0.96
Price-To-Earnings
Trailing P/E Ratio-13.18
Forward P/E Ratio-26.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$404.90 million
Price / Sales0.79
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.57 per share
Price / Book6.47
Profitability
EPS (Most Recent Fiscal Year)($0.28)
Net Income$-23,890,000.00
Net Margins-5.79%
Return on Equity-42.24%
Return on Assets-5.17%
Miscellaneous
Employees998
Outstanding Shares86,660,000
Market Cap$327.58 million
OptionableOptionable
Accuray (NASDAQ:ARAY) Frequently Asked Questions
What is Accuray's stock symbol?
Accuray trades on the NASDAQ under the ticker symbol "ARAY."
How were Accuray's earnings last quarter?
Accuray Incorporated (NASDAQ:ARAY) issued its earnings results on Tuesday, October, 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.02. The medical equipment provider had revenue of $95.83 million for the quarter, compared to the consensus estimate of $95.10 million. Accuray had a negative net margin of 5.79% and a negative return on equity of 42.24%. During the same period last year, the firm earned ($0.11) earnings per share. View Accuray's Earnings History.
When is Accuray's next earnings date?
What price target have analysts set for ARAY?
4 analysts have issued twelve-month price objectives for Accuray's stock. Their predictions range from $3.90 to $6.00. On average, they anticipate Accuray's share price to reach $5.30 in the next year. This suggests a possible upside of 43.6% from the stock's current price. View Analyst Price Targets for Accuray.
What is the consensus analysts' recommendation for Accuray?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.
What are Wall Street analysts saying about Accuray stock?
Here are some recent quotes from research analysts about Accuray stock:
- 1. BTIG Research analysts commented, "While we were out sick, Accuray posted a ~$6M revenue beat but missed gross order expectations. Although the company fell short of its guided 5% y/y growth in gross orders for FY18, we liked the sales step up, strong revenue guidance for FY19, and the increasing funnel of anticipated multi- system orders. The company’s decision to move away from annual gross order guidance may bother some but is probably the correct move given mgmt’s inability to consistently accurately predict this. Pinning down an order growth rate is likely to become more challenging, as we expect more multi-system orders to add timing unpredictability and more lumpiness to quarterly numbers. Overall, while it may be tougher – at least near term – to get visibility into quarterly orders, we see larger multi-unit bookings as a win for ARAY." (8/22/2018)
- 2. According to Zacks Investment Research, "Accuray successfully rides on the market’s solid response to the Radixact platform. Recently, the Radixact X9 received the AERB approval for its sale in India. Growing adoption of non-surgical treatment options, successful execution of restructuring plans and accretive acquisitions are other positives. A series of software upgradation has been another growth driver. These upgrades include integrated data management system (IDMS) and Accuray Precision Treatment Planning Software. On the flip side, the company lowered the EBITDA expectations largely due to strategic investments and lower-than-expected gross margins. Long sales and implementation cycle of the CyberKnife and TomoTherapy systems is a headwind, keeping margins under pressure. Furthermore, unfavorable product mix, declining service revenues, sluggish macro-economic conditions and pricing headwinds are major concerns. Accuray has underperformed the industry in the past three months." (7/3/2018)
Has Accuray been receiving favorable news coverage?
Press coverage about ARAY stock has trended negative on Tuesday, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accuray earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near future.
Who are some of Accuray's key competitors?
Some companies that are related to Accuray include K2M Group (KTWO), Nevro (NVRO), Luminex (LMNX), AtriCure (ATRC), Cryolife (CRY), Orthofix Medical (OFIX), Cardiovascular Systems (CSII), Intersect ENT (XENT), Tactile Systems Technology (TCMD), AngioDynamics (ANGO), Cerus (CERS), SurModics (SRDX), OraSure Technologies (OSUR), SI-Bone (SIBN) and LeMaitre Vascular (LMAT).
Who are Accuray's key executives?
Accuray's management team includes the folowing people:
- Mr. Joshua H. Levine, Pres, CEO & Director (Age 60)
- Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 55)
- Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 59)
- Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 45)
- Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer
Who are Accuray's major shareholders?
Accuray's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.86%), Vanguard Group Inc (7.06%), Vanguard Group Inc. (7.06%), Renaissance Technologies LLC (6.13%), Neuberger Berman Group LLC (4.97%) and Russell Investments Group Ltd. (4.62%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Kelly Londy, Kevin Waters and Shigeyuki Hamamatsu. View Institutional Ownership Trends for Accuray.
Which institutional investors are selling Accuray stock?
ARAY stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Vanguard Group Inc., Vanguard Group Inc, Alambic Investment Management L.P., Morgan Stanley, BlackRock Inc., Russell Investments Group Ltd. and Neuberger Berman Group LLC. Company insiders that have sold Accuray company stock in the last year include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, Kevin Waters and Shigeyuki Hamamatsu. View Insider Buying and Selling for Accuray.
Which institutional investors are buying Accuray stock?
ARAY stock was purchased by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., Marshall Wace LLP, Renaissance Technologies LLC, Assenagon Asset Management S.A., JPMorgan Chase & Co., JPMorgan Chase & Co., Putnam Investments LLC and Heartland Advisors Inc.. View Insider Buying and Selling for Accuray.
How do I buy shares of Accuray?
Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accuray's stock price today?
One share of ARAY stock can currently be purchased for approximately $3.69.
How big of a company is Accuray?
Accuray has a market capitalization of $327.58 million and generates $404.90 million in revenue each year. The medical equipment provider earns $-23,890,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis. Accuray employs 998 workers across the globe.
What is Accuray's official website?
How can I contact Accuray?
Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]
MarketBeat Community Rating for Accuray (NASDAQ ARAY)
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
